Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.

Autor: Stelljes, Matthias, Advani, Anjali S, DeAngelo, Daniel J, Wang, Tao, Neuhof, Alexander, Vandendries, Erik, Kantarjian, Hagop, Jabbour, Elias
Zdroj: Clinical Lymphoma, Myeloma & Leukemia; Sep2022, Vol. 22 Issue 9, pe836-e843, 8p
Databáze: Complementary Index
Externí odkaz: